1. Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal injection of Ozurdex (®) implant in patients with persistent diabetic macular edema, with six-month follow-up. <em>Ophthalmol Eye Dis.</em> 2016;8:11-16.
2. Lowder C, Belfort Jr R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. <em>Arch Ophthalmol.</em> 2011;129(5):545-553.
3. Schmitz K, Maier M, Clemens CR, et al. Zuverlässigkeit und Sicherheit von intravitrealen Ozurdex-injektionen. Die ZERO-studie. <em>Ophthalmologe</em>. 2014;111(1):44-52. doi:10.1007/s00347-012-2737-2
4. Agrawal R, Fernandez-Sanz G, Bala S, et al. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. <em>Br J Ophthalmol.</em> 2014;98(7):961-963.
5. Poornachandra B, Kumar VBM, Jayadev C, et al. Immortal Ozurdex: a 10-month follow-up of an intralenticular implant. <em>Indian J Ophthalmol</em>. 2017;65(3):255-257.
6. Coca-Robinot J, Casco-Silva B, Armad Maresca F, et al. Accidental injection of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. <em>Eur J Ophthalmol.</em> 2014;24(4):633-666.
7. Regan K, Blake CR, Lukowski ZL, et al. Intralenticular Ozurdex- one year later. <em>Case Rep Ophthalmol.</em> 2017;8(3):590-594.
8. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. <em>Ophthalmology.</em> 2014; 121(1):67-71.
9. Munteanu M, Rosca C. Repositioning and follow-up of intralenticular dexamethasone implant. <em>J Cataract Refract Surg. </em>2013;39(8):1271-1274.
10. Sekeroglu MA, Anayol MA, Koc F et al. Intralenticular sustained-release dexamethasone implant: is it still effective on macular edema. <em>Case Rep Ophthalmol.</em> 2016;7(1):85-89.
11. Costello MA, Liu J, Wang Y, et al. Reverse engineering the Ozurdex dexamethasone intravitreal implant. <em>Int J Pharm. </em>2023;634:122625.
12. Meyer CH, Rodrigues EB, Michels S, et al. Incidence of damage to the crystalline lens during intravitreal injections. <em>J Ocul Pharmacol Ther.</em> 2010;26(5):491-495.
13. Valverde-Megias A, Hernandez-Ruiz S, Cifuentes-Canorea P, et al. Intralenticular Ozurdex implant: what to do and how. <em>J Fr Ophthalmol</em>. 2018;41(4):149-150.
14. Baskan B, Cıcek A, Gulhan A, Gundogan M, Goktas S. Ozurdex completely located inside a crystallized lens-results of 14 months. <em>Am J Ophthalmol Case Rep.</em> 2016;4:38-40.
15. Çiloğlu E, İnan P. Intralenticular dexamethasone: a case report. <em>J Retina Vitreous.</em> 2021;30(2).
16. Fasce F, Battaglia PM, Knutsson KA, et al. Accidental injection of dexamethasone intravitreal implant in the crystalline lens. <em>Acta Ophthalmol.</em> 2014;92(4):330-331.
17. Kocak N, Ozturk T, Karahan E, Kaynak S. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule. <em>Indian J Ophthalmol. </em>2014;62(11):1086-1088.
18. Srinivasan P, Jayadev C Shetty R. The nomadic Ozurdex®: anterior migration of the dexamethasone implant and back!. <em>Oman J Ophthalmol. </em>2017;10(2):109-111.
19. Kumar A, Ambiya V, Kapoor G, Arora A. Wandering Ozurdex in eyes with scleral fixated intraocular lens and its management: a report of two cases.<em> J Curr Ophthalmol. </em>2019;31(3):345-348.